CAS NO: | 1609281-86-8 |
包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
Cas No. | 1609281-86-8 |
化学名 | (S)-5-(4-(3,5-dimethylisoxazol-4-yl)-2-(pyrrolidin-3-yloxy)phenyl)-2-ureidothiophene-3-carboxamide |
Canonical SMILES | CC1=NOC(C)=C1C2=CC(O[C@H]3CCNC3)=C(C4=CC(C(N)=O)=C(NC(N)=O)S4)C=C2 |
分子式 | C21H23N5O4S |
分子量 | 441.5 |
溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Target: IKK2 IC50: N/A AZD3264 is a novel and small molecule IKK2 inhibitor. IKK2 serves as a protein subunit of IκB kinase, which is a component of the cytokine-activated intracellular signaling pathway involved in triggering immune responses. IKK's activity induces the activation of a transcription factor NF-κB. Activated IKK2 phosphorylates IκB (IκBα), which binds NF-κB to inhibit its function. Phosphorylated IκB is degraded by the ubiquitination pathway, freeing NF-κB, and allowing its entry into the cell nucleus where it activates target genes involved in inflammation and other immune responses. Suppression of IKK2 has been identified as a potential therapeutic option to treat cancer and inflammatory diseases, including asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis [1]. In vitro: AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis [2]. In vivo: N/A References: |